JP2017503030A5 - - Google Patents

Download PDF

Info

Publication number: JP2017503030A5
Authority: JP; Japan
Prior art keywords: composition; receptor antagonist; crf1 receptor; nbi; item
Prior art date: 2015-01-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

JP2016565135A

Other languages

English (en)

Japanese (ja)

Other versions

JP6585625B2 (ja

JP2017503030A (ja

Filing date

2015-01-21

Publication date

2018-03-01

2015-01-21 Application filed filed Critical

2015-01-21 Priority claimed from PCT/US2015/012315 external-priority patent/WO2015112642A1/en

2017-01-26 Publication of JP2017503030A publication Critical patent/JP2017503030A/ja

2018-03-01 Publication of JP2017503030A5 publication Critical patent/JP2017503030A5/ja

2019-03-11 Priority to JP2019043466A priority Critical patent/JP6936825B2/ja

2019-10-02 Application granted granted Critical

2019-10-02 Publication of JP6585625B2 publication Critical patent/JP6585625B2/ja

Status Active legal-status Critical Current

2035-01-21 Anticipated expiration legal-status Critical

Links

239000002464 receptor antagonist Substances 0.000 claims description 36
229940044551 receptor antagonist Drugs 0.000 claims description 36
108091005471 CRHR1 Proteins 0.000 claims description 35
239000000203 mixture Substances 0.000 claims description 21
239000000055 Corticotropin-Releasing Hormone Substances 0.000 claims description 12
IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims description 12
229960000258 corticotropin Drugs 0.000 claims description 12
230000027288 circadian rhythm Effects 0.000 claims description 10
238000010494 dissociation reaction Methods 0.000 claims description 9
230000005593 dissociations Effects 0.000 claims description 9
VKHVAUKFLBBZFJ-SFHVURJKSA-N 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-n-[(1s)-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]pyrazolo[1,5-a]pyrimidin-7-amine Chemical compound N([C@@H](CC)C=1ON=C(C)N=1)C(N1N=C2C)=CC(C)=NC1=C2C1=CC=C(OC)C=C1C VKHVAUKFLBBZFJ-SFHVURJKSA-N 0.000 claims description 8
-1 3-methyl-1 , 2,4-oxadiazol-5-yl Chemical group 0.000 claims description 6
150000001875 compounds Chemical class 0.000 claims description 6
AKLMUGFDGONMAA-UHFFFAOYSA-N 268545-87-5 Chemical compound C=12C3=NC(C)=CC=1N(C(CCC)CCC)CCN2N=C3C1=CC=C(Cl)C=C1Cl AKLMUGFDGONMAA-UHFFFAOYSA-N 0.000 claims description 5
QBBJSFUFEUXTNU-UHFFFAOYSA-N 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-n-pentan-3-ylpyrazolo[1,5-a]pyrimidin-7-amine Chemical compound CC1=NN2C(NC(CC)CC)=CC(C)=NC2=C1C1=CC=C(OC)C=C1C QBBJSFUFEUXTNU-UHFFFAOYSA-N 0.000 claims description 5
ANNRUWYFVIGKHA-UHFFFAOYSA-N 3-[6-(dimethylamino)-4-methylpyridin-3-yl]-2,5-dimethyl-n,n-dipropylpyrazolo[1,5-a]pyrimidin-7-amine Chemical compound CC1=NN2C(N(CCC)CCC)=CC(C)=NC2=C1C1=CN=C(N(C)C)C=C1C ANNRUWYFVIGKHA-UHFFFAOYSA-N 0.000 claims description 5
IEAKXXNRGSLYTQ-DEOSSOPVSA-N SSR 125543 Chemical compound C1=C(C)C(OC)=CC(Cl)=C1C1=C(C)SC(N(CC#C)[C@@H](CC2CC2)C=2C=C(F)C(C)=CC=2)=N1 IEAKXXNRGSLYTQ-DEOSSOPVSA-N 0.000 claims description 5
206010010356 Congenital anomaly Diseases 0.000 claims description 4
230000001780 adrenocortical effect Effects 0.000 claims description 4
206010020718 hyperplasia Diseases 0.000 claims description 4
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
JAVQQLIFVFPAQG-UHFFFAOYSA-N 2-phenyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound N=1C=2NC=CC=2C(N)=NC=1C1=CC=CC=C1 JAVQQLIFVFPAQG-UHFFFAOYSA-N 0.000 claims description 3
DBPWSSGDRRHUNT-CEGNMAFCSA-N 17α-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DBPWSSGDRRHUNT-CEGNMAFCSA-N 0.000 claims description 2
PEHVGBZKEYRQSX-UHFFFAOYSA-N 7-deaza-adenine Chemical compound NC1=NC=NC2=C1C=CN2 PEHVGBZKEYRQSX-UHFFFAOYSA-N 0.000 claims description 2
GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 claims 2
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
208000005676 Adrenogenital syndrome Diseases 0.000 claims 1
208000008448 Congenital adrenal hyperplasia Diseases 0.000 claims 1
WPFZGADUIUVTCF-UHFFFAOYSA-N pyrazolo[1,5-a]pyrimidin-7-amine Chemical compound NC1=CC=NC2=CC=NN12 WPFZGADUIUVTCF-UHFFFAOYSA-N 0.000 claims 1
238000000034 method Methods 0.000 description 13

JP2016565135A 2014-01-21 2015-01-21 先天性副腎皮質過形成の処置のためのｃｒｆ１レセプターアンタゴニスト Active JP6585625B2 (ja)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
JP2019043466A JP6936825B2 (ja)	2014-01-21	2019-03-11	先天性副腎皮質過形成の処置のためのｃｒｆ１レセプターアンタゴニスト

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US201461929941P	2014-01-21	2014-01-21
US61/929,941		2014-01-21
US201461981033P	2014-04-17	2014-04-17
US61/981,033		2014-04-17
US201462069155P	2014-10-27	2014-10-27
US62/069,155		2014-10-27
PCT/US2015/012315 WO2015112642A1 (en)	2014-01-21	2015-01-21	Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2019043466A Division JP6936825B2 (ja)	2014-01-21	2019-03-11	先天性副腎皮質過形成の処置のためのｃｒｆ１レセプターアンタゴニスト

Publications (3)

Publication Number	Publication Date
JP2017503030A JP2017503030A (ja)	2017-01-26
JP2017503030A5 true JP2017503030A5 (2)	2018-03-01
JP6585625B2 JP6585625B2 (ja)	2019-10-02

Family

ID=52450623

Family Applications (5)

Application Number	Title	Priority Date	Filing Date
JP2016565135A Active JP6585625B2 (ja)	2014-01-21	2015-01-21	先天性副腎皮質過形成の処置のためのｃｒｆ１レセプターアンタゴニスト
JP2019043466A Active JP6936825B2 (ja)	2014-01-21	2019-03-11	先天性副腎皮質過形成の処置のためのｃｒｆ１レセプターアンタゴニスト
JP2020099865A Active JP7104743B2 (ja)	2014-01-21	2020-06-09	先天性副腎皮質過形成の処置のためのｃｒｆ１レセプターアンタゴニスト
JP2021184620A Withdrawn JP2022010260A (ja)	2014-01-21	2021-11-12	先天性副腎皮質過形成の処置のためのｃｒｆ１レセプターアンタゴニスト
JP2024079330A Pending JP2024098001A (ja)	2014-01-21	2024-05-15	先天性副腎皮質過形成の処置のためのｃｒｆ１レセプターアンタゴニスト

Family Applications After (4)

Application Number	Title	Priority Date	Filing Date
JP2019043466A Active JP6936825B2 (ja)	2014-01-21	2019-03-11	先天性副腎皮質過形成の処置のためのｃｒｆ１レセプターアンタゴニスト
JP2020099865A Active JP7104743B2 (ja)	2014-01-21	2020-06-09	先天性副腎皮質過形成の処置のためのｃｒｆ１レセプターアンタゴニスト
JP2021184620A Withdrawn JP2022010260A (ja)	2014-01-21	2021-11-12	先天性副腎皮質過形成の処置のためのｃｒｆ１レセプターアンタゴニスト
JP2024079330A Pending JP2024098001A (ja)	2014-01-21	2024-05-15	先天性副腎皮質過形成の処置のためのｃｒｆ１レセプターアンタゴニスト

Country Status (24)

Country	Link
US (5)	US20170020877A1 (2)
EP (2)	EP3096756B1 (2)
JP (5)	JP6585625B2 (2)
KR (2)	KR102258522B1 (2)
CN (2)	CN106102740A (2)
AU (4)	AU2015209452C1 (2)
BR (1)	BR112016016975B1 (2)
CA (2)	CA2936974A1 (2)
DK (1)	DK3096756T3 (2)
ES (1)	ES2984706T3 (2)
FI (1)	FI3096756T3 (2)
HR (1)	HRP20241046T1 (2)
HU (1)	HUE068315T2 (2)
IL (5)	IL304134B2 (2)
LT (1)	LT3096756T (2)
MX (3)	MX389004B (2)
NZ (1)	NZ722122A (2)
PL (1)	PL3096756T3 (2)
PT (1)	PT3096756T (2)
RS (1)	RS65839B1 (2)
RU (1)	RU2718918C2 (2)
SI (1)	SI3096756T1 (2)
SM (1)	SMT202400361T1 (2)
WO (1)	WO2015112642A1 (2)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RS65839B1 (sr) *	2014-01-21	2024-09-30	Neurocrine Biosciences Inc	Crf1 receptor antagonisti za tretman kongenitalne adrenalne hiperplazije
EP3107569A4 (en)	2014-02-20	2018-02-21	Alder Biopharmaceuticals, Inc.	Anti-acth antibodies and use thereof
JP7187037B2 (ja)	2016-09-07	2022-12-12	ザリージェンツオブザユニバーシティオブカリフォルニア	ｐ－タウを減少させ、認知機能を改善させるアロステリック副腎皮質刺激ホルモン放出因子受容体１（ＣＲＦＲ１）アンタゴニスト
WO2019036503A1 (en) *	2017-08-14	2019-02-21	Spruce Biosciences, Inc.	CORTICOTROPIN RELEASE FACTOR RECEPTOR ANTAGONISTS
EP4643950A3 (en) *	2018-04-27	2026-01-14	Spruce Biosciences, Inc.	Methods for treating testicular and ovarian adrenal rest tumors
JP7532328B2 (ja) *	2018-12-07	2024-08-13	ニューロクラインバイオサイエンシーズ，インコーポレイテッド	先天性副腎過形成を処置するためのｃｒｆ１受容体アンタゴニスト、その医薬製剤および固体形態
US20220023266A1 (en) *	2018-12-07	2022-01-27	Neurocrine Biosciences, Inc.	Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
JP2022541550A (ja) *	2019-07-19	2022-09-26	スプルースバイオサイエンシーズ，インク．	先天性副腎過形成を処置する方法
JP7623365B2 (ja) *	2019-09-27	2025-01-28	ニューロクラインバイオサイエンシーズ，インコーポレイテッド	Ｃｒｆ受容体アンタゴニストおよび使用方法
CR20220624A (es) *	2020-06-10	2023-07-06	Sanofi Sa	Antagonista del receptor crf1 para el tratamiento de la hiperplasia suprarrenal congénita
KR20240023691A (ko)	2020-08-12	2024-02-22	스프루스 바이오사이언시스 인코포레이티드	다낭성 난소 증후군을 치료하기 위한 방법 및 조성물
MD20210019A2 (ro)	2021-04-12	2022-10-31	Максим МАСЮТИН	Metodă de tratament a hiperplaziei suprarenale congenitale, cauzate de deficit de 21-hidroxilază cu debut tardiv prin regimul de glucocorticoizi adaptat individual
US11708372B2 (en)	2021-11-19	2023-07-25	Spruce Biosciences, Inc.	Crystalline composition of tildacerfont and methods of use and preparation thereof

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS4949582B1 (2)	1969-01-20	1974-12-27
US4783443A (en)	1986-03-03	1988-11-08	The University Of Chicago	Amino acyl cephalosporin derivatives
FR2692893B1 (fr)	1992-06-24	1994-09-02	Sanofi Elf	Dérivés alkylamino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
US6664261B2 (en)	1996-02-07	2003-12-16	Neurocrine Biosciences, Inc.	Pyrazolopyrimidines as CRF receptor antagonists
TW477787B (en)	1996-08-27	2002-03-01	Pfizer	Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
US6159980A (en)	1996-09-16	2000-12-12	Dupont Pharmaceuticals Company	Pyrazinones and triazinones and their derivatives thereof
FR2754258B1 (fr)	1996-10-08	1998-12-31	Sanofi Sa	Derives d'aminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
DE69818248T2 (de)	1997-04-22	2004-06-17	Janssen Pharmaceutica N.V.	Chinolin- und chinazolin-derivate als crf antagonisten
WO1999010350A1 (en)	1997-08-22	1999-03-04	Du Pont Pharmaceuticals Company	NITROGEN SUBSTITUTED IMIDAZO[4,5-c]PYRAZOLES AS CORTICOTROPIN RELEASING HORMONE ANTAGONISTS
US6531475B1 (en)	1998-11-12	2003-03-11	Neurocrine Biosciences, Inc.	CRF receptor antagonists and methods relating thereto
CA2369553A1 (en)	1999-04-02	2000-10-12	Raymond F. Horvath	N-benzimidazolylmethyl and n-indolylmethyl-benzamides and their use as crf modulators
FR2796380B3 (fr)	1999-07-15	2001-08-17	Sanofi Synthelabo	Nouveaux derives d'aminothiazoles, leur preparation et les compositions pharmaceutiques les contenant
FR2802530B1 (fr)	1999-12-17	2002-02-22	Sanofi Synthelabo	Nouveaux derives amino substitues ramifies du 3-amino-1-phenyl-1h[1,2,4]triazole, procedes pour leur preparation et compositions pharmaceutiques les contenant
US7276526B2 (en)	2001-07-13	2007-10-02	Bristol-Myers Squibb Pharma Company	Substituted thiazoles and oxazoles as corticotropin releasing hormone ligands
WO2005079807A1 (en)	2004-02-13	2005-09-01	Pfizer Products Inc.	Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists
EP1781257B1 (en)	2004-08-13	2018-12-19	Emisphere Technologies, Inc.	Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
GB0519957D0 (en)	2005-09-30	2005-11-09	Sb Pharmco Inc	Chemical compound
US7652035B2 (en)	2004-10-19	2010-01-26	Neurocrine Bioscience, Inc.	CRF receptor antagonists and methods relating thereto
EP1869049B1 (en)	2005-03-21	2009-03-04	Eli Lilly And Company	Imidazopyridazine compounds
US7557103B2 (en)	2005-04-05	2009-07-07	Eli Lilly And Company	Imidazopyridazine compounds
TWI370820B (en)	2005-04-27	2012-08-21	Takeda Pharmaceutical	Fused heterocyclic compounds
JPWO2006126718A1 (ja)	2005-05-27	2008-12-25	田辺三菱製薬株式会社	ピラゾロピリミジン誘導体
WO2007054719A2 (en)	2005-11-10	2007-05-18	Topotarget Uk Limited	Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer alone or in combination with chemotherapeutic agent
WO2007069565A1 (ja)	2005-12-12	2007-06-21	Ono Pharmaceutical Co., Ltd.	二環式複素環化合物
JPWO2007069671A1 (ja)	2005-12-15	2009-05-21	小野薬品工業株式会社	二環式複素環化合物
PL1982178T3 (pl)	2006-02-07	2014-02-28	Phenoquest Ag	Sposoby leczenia zaburzeń afektywnych
EP1834641A1 (en)	2006-03-16	2007-09-19	Sanofi-Aventis	Use of CRF1 receptor antagonists for preparing a drug for treating metabolic syndrome and/or obesity and/or dyslipoproteinemia
US20090306137A1 (en)	2006-05-22	2009-12-10	Wolfgang Curt D	Treatment for depressive disorders
HRP20100516T1 (hr)	2006-09-20	2010-10-31	Eli Lilly And Company	Tiazolpirazolopirimidini kao antagonisti receptora crf1
JP5184536B2 (ja)	2006-09-20	2013-04-17	イーライリリーアンドカンパニー	チオフェンピラゾロピリミジン化合物
US20100056515A1 (en)	2006-10-25	2010-03-04	Kazuyoshi Aso	Benzimidazole compounds
WO2008083070A1 (en)	2006-12-29	2008-07-10	Neurogen Corporation	Crf1 receptor ligands comprising fused bicyclic heteroaryl moieties
JP2010514672A (ja)	2006-12-29	2010-05-06	武田薬品工業株式会社	Ｃｒｆアンタゴニスト活性を有する縮合複素環化合物
TW200902019A (en)	2007-04-26	2009-01-16	Ono Pharmaceutical Co	Dicyclic heterocyclic compound
WO2009008552A1 (en)	2007-07-11	2009-01-15	Taisho Pharmaceutical Co., Ltd.	8-aryl-4-alkylpyrrolo[2,3,4-de]quinolin-5(4h)-one and 8-aryl-4-alkyl-4,5-dihydropyrrolo[2,3,4-de]quinolin-5-ol derivatives
WO2009144632A1 (en)	2008-05-30	2009-12-03	Pfizer Limited	Novel compounds
US7932256B2 (en)	2008-07-31	2011-04-26	Bristol-Myers Squibb Company	(S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile: a pyrazinone modulator of corticotropin-releasing factor receptor activity
JP2011529899A (ja)	2008-07-31	2011-12-15	ブリストル−マイヤーズスクイブカンパニー	副腎皮質刺激ホルモン放出因子受容体活性のモジュレーターとしての置換カルバメート誘導体
US7994203B2 (en)	2008-08-06	2011-08-09	Novartis Ag	Organic compounds
US8273900B2 (en)	2008-08-07	2012-09-25	Novartis Ag	Organic compounds
JP5800428B2 (ja)	2008-11-03	2015-10-28	ジンテスゲゼルシャフトミットベシュレンクテルハフツング	調整式ロッド組立体
US8551996B2 (en)	2009-02-20	2013-10-08	Emory University	Compounds, compositions, methods of synthesis, and methods of treatment
HUP0900267A2 (en)	2009-04-30	2011-03-28	Sanofi Aventis	Process for preparing of thiazole amines and intermediates thereof
AR078521A1 (es)	2009-10-08	2011-11-16	Eisai R&D Man Co Ltd	Compuesto pirazolotiazol
EP2487177A1 (en)	2009-10-08	2012-08-15	Eisai R&D Management Co., Ltd.	Pyrazoloxazole compound
AR080056A1 (es)	2010-02-01	2012-03-07	Novartis Ag	Derivados de ciclohexil-amida como antagonistas de los receptores de crf
JP2013518085A (ja)	2010-02-01	2013-05-20	ノバルティスアーゲー	ＣＲＦ−１受容体アンタゴニストとしてのピラゾロ［５，１ｂ］オキサゾール誘導体
JP5748777B2 (ja)	2010-02-02	2015-07-15	ノバルティスアーゲー	Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体
SG10201608579UA (en)	2012-04-13	2016-12-29	Epizyme Inc	Combination therapy for treating cancer
US20150278438A1 (en) *	2012-04-23	2015-10-01	MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.	Genetic predictors of response to treatment with crhr1 antagonists
US20150094310A1 (en)	2012-04-23	2015-04-02	Holsboermaschmeyer Neurochemie Gmbh	Crhr1 antagonists for use in the treatment of patients having crh overactivity
RS65839B1 (sr) *	2014-01-21	2024-09-30	Neurocrine Biosciences Inc	Crf1 receptor antagonisti za tretman kongenitalne adrenalne hiperplazije
WO2016065177A1 (en)	2014-10-22	2016-04-28	The Trustees Of The University Of Pennsylvania	Method of treating depression and other stress related disorders
US9714246B2 (en)	2015-02-06	2017-07-25	Neurocrine Biosciences, Inc.	[9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto
EP3277836B1 (en)	2015-04-02	2019-02-27	HMNC Value GmbH	Method of treatment using genetic predictors of a response to treatment with ssr-125543
WO2018012066A1 (ja) *	2016-07-14	2018-01-18	株式会社コナミデジタルエンタテインメント	ゲームシステム、端末装置及びプログラム
EP3548035A4 (en)	2016-11-30	2020-07-22	Case Western Reserve University	COMBINATIONS OF 15-PGDH INHIBITORS WITH CORCOSTEROIDS AND / OR TNF INHIBITORS AND THEIR USES
WO2018219804A1 (en)	2017-06-02	2018-12-06	Bayer Pharma Aktiengesellschaft	Self-microemulsifying drug delivery systems
JP7285222B2 (ja)	2017-08-14	2023-06-01	スプルースバイオサイエンシズインコーポレイテッド	副腎皮質刺激ホルモン放出因子受容体拮抗薬
WO2019036503A1 (en)	2017-08-14	2019-02-21	Spruce Biosciences, Inc.	CORTICOTROPIN RELEASE FACTOR RECEPTOR ANTAGONISTS
EP4643950A3 (en)	2018-04-27	2026-01-14	Spruce Biosciences, Inc.	Methods for treating testicular and ovarian adrenal rest tumors
US20220023266A1 (en)	2018-12-07	2022-01-27	Neurocrine Biosciences, Inc.	Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
JP2022541550A (ja)	2019-07-19	2022-09-26	スプルースバイオサイエンシーズ，インク．	先天性副腎過形成を処置する方法
JP7623365B2 (ja)	2019-09-27	2025-01-28	ニューロクラインバイオサイエンシーズ，インコーポレイテッド	Ｃｒｆ受容体アンタゴニストおよび使用方法
TW202134241A (zh)	2019-12-04	2021-09-16	美商紐羅克里生物科學有限公司	Ｃｒｆ受體拮抗劑及使用方法
CR20220624A (es)	2020-06-10	2023-07-06	Sanofi Sa	Antagonista del receptor crf1 para el tratamiento de la hiperplasia suprarrenal congénita
US20240024330A1 (en)	2020-08-26	2024-01-25	Neurocrine Biosciences, Inc.	Crf receptor antagonists and methods of use

2015
- 2015-01-21 RS RS20240910A patent/RS65839B1/sr unknown
- 2015-01-21 KR KR1020167022375A patent/KR102258522B1/ko active Active
- 2015-01-21 ES ES15702917T patent/ES2984706T3/es active Active
- 2015-01-21 PT PT157029174T patent/PT3096756T/pt unknown
- 2015-01-21 EP EP15702917.4A patent/EP3096756B1/en active Active
- 2015-01-21 LT LTEPPCT/US2015/012315T patent/LT3096756T/lt unknown
- 2015-01-21 RU RU2016133972A patent/RU2718918C2/ru active
- 2015-01-21 KR KR1020217015795A patent/KR20210064407A/ko not_active Ceased
- 2015-01-21 FI FIEP15702917.4T patent/FI3096756T3/fi active
- 2015-01-21 MX MX2016009499A patent/MX389004B/es unknown
- 2015-01-21 JP JP2016565135A patent/JP6585625B2/ja active Active
- 2015-01-21 BR BR112016016975-1A patent/BR112016016975B1/pt active IP Right Grant
- 2015-01-21 CA CA2936974A patent/CA2936974A1/en active Pending
- 2015-01-21 HR HRP20241046TT patent/HRP20241046T1/hr unknown
- 2015-01-21 IL IL304134A patent/IL304134B2/en unknown
- 2015-01-21 WO PCT/US2015/012315 patent/WO2015112642A1/en not_active Ceased
- 2015-01-21 EP EP24174933.2A patent/EP4450070A1/en active Pending
- 2015-01-21 NZ NZ722122A patent/NZ722122A/en unknown
- 2015-01-21 CN CN201580005270.4A patent/CN106102740A/zh active Pending
- 2015-01-21 IL IL317035A patent/IL317035A/en unknown
- 2015-01-21 CN CN202010134003.XA patent/CN111228274A/zh active Pending
- 2015-01-21 CA CA3155599A patent/CA3155599A1/en active Pending
- 2015-01-21 DK DK15702917.4T patent/DK3096756T3/da active
- 2015-01-21 US US15/113,362 patent/US20170020877A1/en not_active Abandoned
- 2015-01-21 HU HUE15702917A patent/HUE068315T2/hu unknown
- 2015-01-21 SM SM20240361T patent/SMT202400361T1/it unknown
- 2015-01-21 PL PL15702917.4T patent/PL3096756T3/pl unknown
- 2015-01-21 IL IL296683A patent/IL296683B2/en unknown
- 2015-01-21 AU AU2015209452A patent/AU2015209452C1/en active Active
- 2015-01-21 SI SI201532025T patent/SI3096756T1/sl unknown
2016
- 2016-07-14 IL IL246783A patent/IL246783B/en unknown
- 2016-07-21 MX MX2021012539A patent/MX2021012539A/es unknown
- 2016-07-21 MX MX2022000080A patent/MX2022000080A/es unknown
2018
- 2018-12-20 US US16/227,127 patent/US10905690B2/en active Active
2019
- 2019-03-11 JP JP2019043466A patent/JP6936825B2/ja active Active
2020
- 2020-06-09 JP JP2020099865A patent/JP7104743B2/ja active Active
- 2020-07-20 AU AU2020207774A patent/AU2020207774B2/en active Active
- 2020-10-20 US US17/074,845 patent/US11730739B2/en active Active
2021
- 2021-08-04 US US17/393,553 patent/US11311544B2/en active Active
- 2021-09-29 IL IL286782A patent/IL286782A/en unknown
- 2021-11-12 JP JP2021184620A patent/JP2022010260A/ja not_active Withdrawn
2022
- 2022-10-31 AU AU2022263460A patent/AU2022263460B2/en active Active
2023
- 2023-07-14 US US18/222,011 patent/US20240058342A1/en active Pending
2024
- 2024-05-15 JP JP2024079330A patent/JP2024098001A/ja active Pending
- 2024-09-17 AU AU2024219813A patent/AU2024219813A1/en active Pending

Publication	Publication Date	Title
JP2017503030A5 (2)	2018-03-01
RU2016133972A (ru)	2018-03-05	Антагонисты рецептора cfr1 для лечения врожденной гиперплазии коры надпочечников
JP2024532735A5 (2)	2025-08-19
EA201991786A1 (ru)	2020-01-16	Способы введения некоторых vmat2-ингибиторов
RU2016141569A (ru)	2018-04-26	Комбинации
JP2016196468A5 (2)	2018-11-01
JP2015516392A5 (2)	2016-06-09
NZ723859A (en)	2023-01-27	Pharmaceutical compositions of therapeutically active compounds and their uses
MY195002A (en)	2022-12-30	Benzoxazepin oxazolidinone compounds and methods of use
JP2015532292A5 (2)	2016-11-24
NZ630457A (en)	2017-05-26	Compounds useful as inhibitors of atr kinase
JP2017513809A5 (2)	2018-03-29
JP2013512923A5 (2)	2014-01-30
NZ718430A (en)	2021-12-24	Heterocyclic compounds and uses thereof
JP2018510132A5 (2)	2019-03-14
MX2013006040A (es)	2013-08-26	Antagonistas del receptor de acido lisofosfatidico y su uso en el tratamiento de fibrosis.
AR083842A1 (es)	2013-03-27	Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a las angiogenesis
MX379425B (es)	2025-03-11	7-bencil-4-(2-metilbencilo) -2,4,6,7,8,9-hexahidroimidazo [1,2-a] pirido [3,4-e] pirimidin-5 (1h) -ona, análogos y sales del mismo y su uso en terapia.
MX2013005445A (es)	2013-07-29	Pirazolopiridinas y el uso de pirazolopiridinas como inhibidores de tirosina cinasa 2 (tyk2).
DE602008003322D1 (de)	2010-12-16	Pyrrolo (3, 2, 1-ij) chinolin-4-on-derivate zur behandlung von tuberkulose
JP2015526391A5 (2)	2016-07-14
NZ752918A (en)	2022-09-30	Treatment of prostate cancer
NZ736055A (en)	2023-05-26	Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators
MX2016015762A (es)	2017-04-10	Derivados de alquilo y arilo de compuestos de 1-oxa-4,9-diazaspiro undecano que tienen actividad multimodal contra el dolor.
SG10201810660QA (en)	2018-12-28	Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain